Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.

British journal of cancer - 1 Apr 2024

Baranyi Marcell, Molnár Eszter, Hegedűs Luca, Gábriel Zsófia, Petényi Flóra Gréta, Bordás Fanni, Léner Violetta, Ranđelović Ivan, Cserepes Mihály, Tóvári József, Hegedűs Balázs, Tímár József

Abstract excerpt

BACKGROUND: Inhibition of mutant KRAS challenged cancer research for decades. Recently, allele-specific inhibitors were approved for the treatment of KRAS-G12C mutant lung cancer. However, de novo and acquired resistance limit their efficacy and several combinations are in clinical development. Our study shows the potential of combining G12C inhibitors with farnesyl-transferase inhibitors. METHODS: Combinations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Enzyme Inhibitors

Share to Lung Neoplasms

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Transferases

Source

Open in PubMed Open full text

Identifiers

PMID: 38278976
DOI: 10.1038/s41416-024-02586-x
PMCID: PMC10951297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.PMID 38278976Read ↗

Current therapy of KRAS-mutant lung cancer.Semantic proximity Read ↗

Inhibition of ULK1/2 and KRAS <sup>G12C</sup> controls tumor growth in preclinical models of lung cancerSemantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancerSemantic proximity Read ↗

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Semantic proximity Read ↗

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read ↗

Current perspectives of KRAS in non-small cell lung cancer.Semantic proximity Read ↗

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.Semantic proximity Read ↗

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic StrategiesSemantic proximity Read ↗

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.Semantic proximity Read ↗

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.